PATENT CLAIM ANALYSIS

Application Number: 15983423
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-10
Patent Classification: ["514", "212070"]

Abstract:
The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

Claim (Index 33):
The compound of  claim 30  which is selected from the group consisting of: 4-chloro-7-(methylthio)-2H-pyrazolo[3,4-c]quinoline; 7-bromo-4-chloro-2H-pyrazolo[3,4-c]quinoline; 6-bromo-4-chloro-2H-pyrazolo[3,4-c]quinoline; 4-chloro-2-(4-methoxybenzyl)-7-(methylthio)-2H-pyrazolo[3,4-c]quinoline; 7-bromo-4-chloro-2-(4-methoxybenzyl)-2H-pyrazolo[3,4-c]quinoline; and 6-bromo-4-chloro-2-(4-methoxybenzyl)-2H-pyrazolo[3,4-c]quinoline.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 93.0
- Lexical Diversity: 1.6087
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14436152', '14436145', '13506509', '13506510', '13509442']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8807434070554196
- 35 USC 102 Novelty (BERT): 0.6056424403954872
- Combined Prediction Score: 0.8532333103894264
- Mean Citation Score: 565.8482339999998
- Max Citation Score: 663.3793
- Similarity Product: 459.5393483462036

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test